<DOC>
	<DOC>NCT02345057</DOC>
	<brief_summary>This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese Type 2 Diabetes Mellitus and Microalbuminuria. The Primary endpoint is the change from baseline in urinary albumin to creatine ratio (UACR).</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Subjects with type 2 diabetes mellitus Male or female subjects aged 20 years or older at informed consent Subjects with urinary albumin to creatine ratio (UACR) ≥ 45 mg/g Cr and &lt; 300 mg/g Cr Estimated glomerular filtration rate by creatinine (eGFRcreat) ≥ 30 mL/min/1.73 m^2 Subjects treated with angiotensinconverting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 3 months prior to treatment period Type 1 diabetes HbA1c (NGSP) &gt;=8.4% Secondary glucose intolerance Subjects diagnosed with nondiabetic nephropathy Nephrotic syndrome Secondary hypertension or malignant hypertension Serum potassium level in any of the following categories: For subjects with eGFRcreat of ≥ 45 mL/min/1.73 m^2, serum potassium level of &lt; 3.5 mEq/L or ≥ 5.1 mEq/L; For subjects with eGFRcreat of ≥ 30 mL/min/1.73 m^2 and &lt; 45 mL/min/1.73 m^2, serum potassium level of &lt; 3.5 mEq/L or ≥ 4.8 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>